NPPA fixes retail prices of 53 drug formulations, including painkillers

The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority's 130th meeting on February 25

Prices of active pharmaceutical ingredients (APIs) have been declining over the past several months, boosting the margins of drug manufacturers. However, many industry insiders attribute this to a predatory pricing strategy by Chinese companies, and
BS Reporter Delhi
1 min read Last Updated : Mar 06 2025 | 9:03 PM IST
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 53 drug formulations, including those used to treat Type-2 diabetes, high cholesterol, bacterial infections, and painkillers.
 
The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority’s 130th meeting on February 25.
 
The revision and fixation of retail prices is a routine exercise undertaken by the NPPA. The drug pricing regulator is vested with the responsibility of fixing and revising the prices of pharmaceutical products, enforcing provisions of the Drug Price Control Order (DPCO), and monitoring the prices of both controlled and decontrolled drugs.
   
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :DoPPharmaceutical companiesPharma salesDrugNPPA

First Published: Mar 06 2025 | 9:03 PM IST

Next Story